3652 results for «303»
3652 results
Valve-in-valve - LIVE case
21 Sep 2023 – From AICT-AsiaPCR 2023
An 84-year-old man, with a history of 23 Carpentier-Edwards in 2004, PPM in 2013, AF on warfarin and impaired LV function (40 %), presented with severe symptomatic stenosis of the surgical bioprosthesis.
A 23 Navitor was implanted without predilatation and with post-dilatation under cerebral protection (Sentinel).
Closure was...
Calcified bifurcation lesion - LIVE case
22 Sep 2023 – From AICT-AsiaPCR 2023
A 59-year-old female patient with type 2 DM, dyslipidaemia, hypothyroidism and impaired LV function (39%) presented with multivessel disease. RCA PCI was performed 3 days ago.
The prox and mid LAD showed a severe calcified lesion including the diagonal. The lesion was prepared using a 1.25 Rotaglide™ ('single-person'...
Complex CTO - LIVE case
22 Sep 2023 – From AICT-AsiaPCR 2023
View the case of an 82-year-old man with history of CABG in 2003 (LIMA LAD, VG RCA, VG CX), PCIs on VG RCA in 2021, PCIs VG-CX in 2022, PPM in 2023 with preserved LV function, and follow the retrograde approach of calcified CX CTO using...
AICT-AsiaPCR 2023 Awards Ceremony
22 Sep 2023 – From AICT-AsiaPCR 2023
With a record number of abstracts and clinical cases submitted this year, the winners of these AICT-AsiaPCR 2023 awards have done an excellent job, as the selection process was extremely rigorous. Find out more about the finalists, their reactions and the works that led them to...
AICT-AsiaPCR 2023 Closing Ceremony
22 Sep 2023 – From AICT-AsiaPCR 2023
As AICT-AsiaPCR 2023 draws to a close, it's time to say thank you to the 950 participants and all those who helped make the conference a success, both on stage and behind the scenes.
Revolutionising coronary calcium treatment: unleashing the potential of intravascular lithotripsy
21 Sep 2023 – From AICT-AsiaPCR 2023
Over the last five years, we have learned that there is a new tool for treating calcium, the greatest enemy of interventional cardiology, which can take various forms: intravascular lithotripsy. In this session, look at how to master this technique in different scenarios, from eccentric calcified...
A hybrid approach in complex PCI: can DES and DCB be complementary?
21 Sep 2023 – From AICT-AsiaPCR 2023
Watch this case-based session to follow discussion about how to choose between DES & DCB, how both can be complementary in diffuse disease as well as in complex PCI, and how physiology and imaging can help guiding PCI, and follow a patient's treatment live.
Leave nothing behind: DCB-only PCI strategy - How DCB evidence has changed today's practice?
22 Sep 2023 – From AICT-AsiaPCR 2023
This session offers an opportunity to stay informed about the recent developments in the International DCB Consensus Group, gain insights into the latest clinical data and real-world experiences related to drug-coated balloon (DCB)-only PCI, understand the safety aspects of DCB in managing complex PCI cases, and...
INFINITY-SWEDEHEART - Percutaneous coronary intervention with a bioadaptor compared to a contemporary drug eluting stent- one year primary outcomes
03 Sep 2024
Daniele Giacoppo provides his take on the main results of the INFINITY-SWEDEHEART trial presented by David Erlinge at the ESC Congress 2024 in London.
Author
Everolimus-eluting stents or bypass surgery for mutivessel coronary artery disease: 10-year outcomes of multicenter randomized controlled BEST trial
20 Sep 2022
Nicola Ryan provides her take on the BEST trial which was presented by Jung-Min Ahn at TCT 2022.
It is a randomised, multicentre, non-inferiority trial comparing PCI with second-generation everolimus-eluting stents and CABG in patients with non-left main multivessel coronary artery disease. At two-year follow-up PCI was shown...
Author
3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications
22 Mar 2022
Ali Nazmi Calik provides his take on the long-term results of the SPYRAL HTN-ON MED trial which demonstrated the durable efficacy and safety of RDN in patients who are already on one to three antihypertensive drugs.
Author
Harmonising optimal strategy for treatment of coronary artery diseases – bleeding risk: HOST-BR
29 Mar 2025
Daniele Giacoppo and Nicola Ammirabile provide their take on the main results of the HOST-BR trial, presented by Hyo-Soo Kim at ACC.25 in Chicago.
Author
Author
